Medicare Enrolled
Dr. Mahmoud Mahafzah, MD, PH.D
Hematology & Oncology · Chicago Ridge, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mahafzah from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mahafzah?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mahafzah
Dr. Mahmoud Mahafzah is a hematology & oncology specialist in Chicago Ridge, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mahafzah performed 5,739 Medicare services across 360 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mahafzah received a total of $10,401 from 76 pharmaceutical and/or device companies across 422 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mahafzah is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 34% volume in IL
$10,401 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,739
Medicare services
Top 34% in IL for hematology & oncology
360
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~302 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,920 | $18 | $70 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
313 | $134 | $530 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
218 | $99 | $380 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
142 | $11 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
38 | $109 | $686 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
35 | $145 | $750 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
30 | $51 | $304 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
28 | $66 | $270 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
15 | $96 | $400 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.2% high complexity
88.2% medium
10.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,401
Total received (2018-2024)
Avg $1,486/year across 7 years
Top 30% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
76
Companies
422
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,726 (74.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,662 (16.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,013 (9.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,352
2023
$1,552
2022
$1,638
2021
$950
2020
$357
2019
$3,145
2018
$1,407
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$152
ABBVIE INC.
$121
Merck Sharp & Dohme LLC
$112
Astellas Pharma US Inc
$92
Novartis Pharmaceuticals Corporation
$82
AstraZeneca Pharmaceuticals LP
$74
Takeda Pharmaceuticals U.S.A., Inc.
$67
Lilly USA, LLC
$60
Genentech USA, Inc.
$55
Eisai Inc.
$43
Stemline Therapeutics Inc.
$43
Gilead Sciences, Inc.
$42
Incyte Corporation
$32
Daiichi Sankyo Inc.
$30
JAZZ PHARMACEUTICALS INC.
$29
Tempus AI, Inc
$28
Fresenius Kabi USA, LLC
$27
Janssen Biotech, Inc.
$25
ARRAY BIOPHARMA INC
$25
GENZYME CORPORATION
$25
Pharmacosmos Therapeutics Inc.
$24
RECORDATI_RARE_DISEASES_INC.
$22
TAIHO ONCOLOGY, INC.
$21
Genmab U.S., Inc.
$21
E.R. Squibb & Sons, L.L.C.
$20
EMD Serono, Inc.
$18
Exelixis Inc.
$18
Karyopharm Therapeutics Inc.
$16
Agios Pharmaceuticals, Inc.
$15
PUMA BIOTECHNOLOGY, INC.
$14
Top 3 companies account for 28.4% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$2,019
Lilly USA, LLC
$808
Merck Sharp & Dohme Corporation
$554
PFIZER INC.
$490
Novartis Pharmaceuticals Corporation
$430
Global Blood Therapeutics, Inc.
$328
Rigel Pharmaceuticals, Inc.
$322
Genentech USA, Inc.
$320
AstraZeneca Pharmaceuticals LP
$310
Merck Sharp & Dohme LLC
$297
GENZYME CORPORATION
$282
Incyte Corporation
$227
Daiichi Sankyo Inc.
$223
E.R. Squibb & Sons, L.L.C.
$197
Takeda Pharmaceuticals U.S.A., Inc.
$188
ABBVIE INC.
$185
Amgen Inc.
$170
Pharmacyclics LLC, An AbbVie Company
$169
Celgene Corporation
$166
Astellas Pharma US Inc
$166
Gilead Sciences, Inc.
$141
TESARO, Inc.
$134
Seagen Inc.
$115
Eisai Inc.
$115
Exelixis Inc.
$106
GlaxoSmithKline, LLC.
$104
Ipsen Biopharmaceuticals, Inc
$93
JAZZ PHARMACEUTICALS INC.
$92
Janssen Pharmaceuticals, Inc
$86
SANOFI-AVENTIS U.S. LLC
$78
AbbVie, Inc.
$71
EMD Serono, Inc.
$68
Genmab U.S., Inc.
$65
AMAG Pharmaceuticals, Inc.
$52
Blueprint Medicines Corporation
$51
Sobi, Inc
$50
Teva Pharmaceuticals USA, Inc.
$48
RECORDATI_RARE_DISEASES_INC.
$47
Grifols USA, LLC
$46
Alexion Pharmaceuticals, Inc.
$46
TOLMAR Pharmaceuticals, Inc.
$45
Stemline Therapeutics Inc.
$43
ARRAY BIOPHARMA INC
$41
Philips Electronics North America Corporation
$40
Taiho Oncology, Inc.
$40
Novo Nordisk Inc
$39
G1 Therapeutics, Inc.
$37
Progenics Pharmaceuticals, Inc.
$36
GE HealthCare
$35
Clovis Oncology, Inc.
$35
EISAI INC.
$31
Karyopharm Therapeutics Inc.
$31
Bayer HealthCare Pharmaceuticals Inc.
$30
Tempus AI, Inc
$28
Fresenius Kabi USA, LLC
$27
Puma Biotechnology, Inc.
$24
Pharmacosmos Therapeutics Inc.
$24
EUSA Pharma (US) LLC
$24
Deciphera Pharmaceuticals Inc.
$24
Pharmacyclics LLC, an AbbVie Company
$23
Sun Pharmaceutical Industries Inc.
$22
ADC Therapeutics America, Inc.
$22
MorphoSys, US Inc.
$22
Mirati Therapeutics, Inc.
$22
Blue Earth Diagnostics Limited
$21
TAIHO ONCOLOGY, INC.
$21
Secura Bio, Inc.
$19
Sysmex Inostics Inc
$17
ImmunoGen, Inc.
$16
Verastem, Inc.
$16
GE HEALTHCARE
$16
Agios Pharmaceuticals, Inc.
$15
Kite Pharma, Inc.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Regeneron Healthcare Solutions, Inc.
$14
PUMA BIOTECHNOLOGY, INC.
$14
Top 3 companies account for 32.5% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Avastin · Axumin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · Balversa · Bavencio · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Copiktra · Cresemba · DARZALEX · DOPTELET · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · Fabhalta · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · Itovebi · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · NINLARO · Neulasta · Novoeight · Nplate · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYLARIFY · Padcev · Perjeta · Pomalyst · Prolastin-C · Prolastin-C Liquid · QINLOCK · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · Rubraca · S&RC Und · SARCLISA · SCEMBLIX · SOLIRIS · SYLVANT · Somatuline Depot · Stimufend · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tavalisse · Tazverik · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Vanflyta · Venclexta · Vitrakvi · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xospata · YONSA · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (74%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
347
Per 100K population
6.7
County median income
$81,797
Nearest hospital
ADVOCATE CHRIST HOSPITAL & MEDICAL CENTER
1.6 mi
1.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mahafzah is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mahafzah experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Mahafzah performed 4,920 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mahafzah receive payments from pharmaceutical companies?
Yes. Dr. Mahafzah received a total of $10,401 from 76 companies across 422 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mahafzah's costs compare to other hematology & oncology specialists in Chicago Ridge?
Dr. Mahafzah's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mahafzah) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago Ridge
Browse hematology & oncology specialists in Chicago Ridge ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology